Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Status:
Recruiting
Trial end date:
2022-08-22
Target enrollment:
Participant gender:
Summary
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel
group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and
immunogenicity of MEDI3506 in adult participants with uncontrolled moderate to severe asthma
on standard of care (SOC). Up to approximately 80 sites globally will participate in this
study.
Approximately 228 participants will be randomized to 3 treatment groups in a 1:1:1 ratio to
receive MEDI3506 dose 1, MEDI3506 dose 2, or placebo.